MEDI5752
MEDI5752 is a pharmaceutical drug with 6 clinical trials. Currently 4 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 1 completed trials
Phase Distribution
Phase Distribution
5
Early Stage
1
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
1 of 1 finished
0.0%
0 ended early
4
trials recruiting
6
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer
A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC
MEDI5752 in Patients With Mature Tertiary Lymphoid Structures Solid Tumors.
MEDI5752 in Japanese Patients With Advanced Solid Tumors.
Clinical Trials (6)
Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer
A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC
MEDI5752 in Patients With Mature Tertiary Lymphoid Structures Solid Tumors.
MEDI5752 in Japanese Patients With Advanced Solid Tumors.
A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6